Lupin 2023

Fera ships erythromycin ophthalmic ointment

Print Friendly, PDF & Email

NEW YORK — Fera Pharmaceuticals has rolled out erythromycin ophthalmic ointment, an antibiotic treatment for the eye.

The company said Tuesday that the ointment is now available in a 1-gram dosages and that it expects ship the 3.5-gram tube size in the next few weeks.

Fera added that it plans for increased supply over the coming weeks, which the company said will help alleviate a supply shortage of the medication.

"Fera has made the completion of erythromycin 1-gram manufacturing transfer a priority, responding to the market shortage," president Frank DellaFera said in a statement. "We are genuinely pleased to be able to help hospitals provide the standard of care they demand."

The product launch stems from a recent acquisition. In July, Fera announced that it acquired all rights, title and interest to seven prescription sterile anti-infective ophthalmic ointment abbreviated new drug applications (ANDAs) marketed by Fougera, a division of Nycomed U.S. Inc.

Besides erythromycin ophthalmic ointment, the products included bacitracin; bacitracin zinc and polymixin B sulfate; gentamicin sulfate, neomycin and polymyxin B sulfates and bacitracin zinc; neomycin and polymyxin B sulfates and dexamethasone; neomycin and polymyxin B sulfates; and bacitracin zinc and hydrocortisone acetate.

Fera said the seven products represent more than 80% of the ophthalmic ointment market volume.

The generic drug maker shipped bacitracin ophthalmic ointment earlier this month, making it available through wholesalers, chain, independent and hospital pharmacies.


NACDS 90th

Comments are closed.